Immune checkpoint crosstalk: CTLA-4/CD80 engagement as a predictor of anti-PD-1/PD-L1 therapy outcome in NSCLC

• by Juan Gumuzio, James Miles, Nicole Quimi, Markel Rementeria, Cristina Cacho, Laura Camacho, Erica J. Geraedts, Kim van Elst, Fernando Aguirre, Peter J. Parker, Véronique Calleja

• July 16, 2026

Surviving CGT's Funding Winter

In the first installment of a new series on the investment environment in cell and gene therapy, Circio CEO Erik Wiklund explains how he had to get creative to raise funds in a difficult biotech market

• by Alun Evans, James Strachan

• July 15, 2026

• 11 min

Sequential tislelizumab plus bronchial arterial chemoembolization and systemic chemotherapy in advanced NSCLC with bulky tumors: efficacy and safety

• by Yaping Quan, Zhengjie Liang, Yunhao Wei, Hao Li, Yan Zeng, Jie Shen, Shengfa Su, Xian Liu, Zhongjun Huang, Minfang Wang, Hongyan Luo, Yong Hu, Jie Peng

• July 15, 2026

Quantitative assessment of inter-observer consistency in target volume delineation following breast-conserving surgery and mastectomy

• by An Yi, Lihong He, Zijie Wang, Xin Liu, Bin Li, Zhuoyu He, Jin Liu, Chunling Jiang

• July 16, 2026